We previously demonstrated that cardiac myosin can use 2-deoxy-ATP (dATP) as an energy substrate, that it enhances contraction and relaxation with minimal effect on calcium-handling properties in vitro, and that contractile enhancement occurs with only minor elevation of cellular [dATP]. Here, we report the effect of chronically enhanced dATP concentration on cardiac function using a transgenic mouse that overexpresses the enzyme ribonucleotide reductase (TgRR), which catalyzes the rate-limiting step in de novo deoxyribonucleotide biosynthesis. Hearts from TgRR mice had elevated left ventricular systolic function compared with wild-type (WT) mice, both in vivo and in vitro, without signs of hypertrophy or altered diastolic function. Isolated cardiomyocytes from TgRR mice had enhanced contraction and relaxation, with no change in Ca 2+ transients, suggesting targeted improvement of myofilament function. TgRR hearts had normal ATP and only slightly decreased phosphocreatine levels by 31 P NMR spectroscopy, and they maintained rate responsiveness to dobutamine challenge. These data demonstrate long-term (at least 5-mo) elevation of cardiac [dATP] results in sustained elevation of basal left ventricular performance, with maintained β-adrenergic responsiveness and energetic reserves. Combined with results from previous studies, we conclude that this occurs primarily via enhanced myofilament activation and contraction, with similar or faster ability to relax. The data are sufficiently compelling to consider elevated cardiac [dATP] as a therapeutic option to treat systolic dysfunction.metabolism | inotropy | cross-bridge cycling A wide variety of cardiac pathologies such as myocardial infarct, dilated cardiomyopathy, and congestive heart failure involve reduced systolic function of ventricles that often results from altered ATP-mediated actin-myosin (cross-bridge) cycling (1-4). The schematic shown in Fig. 1 outlines the basic components of this chemomechanical cycle that are critical to understand how cardiomyocytes use energy to develop tension and shortening: (i) ATP bound to detached myosin is hydrolyzed to ADP and inorganic phosphate (Pi); (ii) myosin binds to actin and undergoes the power-stroke associated with Pi release, tension development, and shortening; (iii) ADP is released from myosin; and (iv) ATP binds and precipitates myosin detachment from actin.We (5-8) and others (9-17) have reported that striated muscle myosin can use most naturally occurring nucleotides to support cross-bridge cycling and contraction to varying degrees. Although most are not as effective as ATP, we found that 2-deoxy-ATP (dATP) is more effective than ATP as a substrate for contraction of demembranated cardiac muscle, augmenting both force and shortening at all levels of Ca 2+ -mediated contractile activation (5-8). Our detailed biochemical and mechanical analysis suggests that dATP increases the rates of both myosin binding and product release (steps 2 and 3 in Fig. 1) (6). More recently, we reported that adenoviral overexpres...